The cause of sarcoidosis is documented as unknown in the packet definition. No causative genes are listed; the known_genes field is empty. Immune granuloma formation is described as the pathological hallmark, but the initiating stimulus is not identified in the available packet data. No inheritance pattern is recorded.

Diagnostic criteria and testing approaches for sarcoidosis are not enumerated in this packet. The condition is characterized as a multisystemic disorder requiring recognition of immune granuloma formation in involved organs, per the definition. Specific diagnostic protocols, imaging criteria, and tissue sampling requirements are not described in the available data fields.

No FDA-approved treatments are listed in this packet. The approved_treatments field and orphan drug entries for sarcoidosis are absent from the available data, reflecting the current regulatory landscape for this condition as documented in the packet.

Outcome and prognosis data are not present in this packet. Clinical course information, remission rates, and long-term trajectory are not enumerated in the available data fields for sarcoidosis.

Ten clinical trials involving sarcoidosis are listed as active or recruiting in this packet. Documented examples include a Phase 2 study of XTMAB-16 in pulmonary sarcoidosis with or without extrapulmonary manifestations by Xentria, Inc. (NCT07680166, not yet recruiting, projected completion 2029) and a Phase 2 study of brepocitinib in cutaneous sarcoidosis by Priovant Therapeutics (NCT06978725, recruiting, start 2025, projected completion 2029). Eight recognized disease subtypes indicate investigational heterogeneity within the condition.